Get Alector alerts:Alector, Inc. (NASDAQ:ALEC – Free Report) – Investment analysts at Cantor Fitzgerald lowered their FY2025 earnings estimates for shares of Alector in a research report issued on Wednesday, October 1st. Cantor Fitzgerald analyst P. Stavropoulos now anticipates that the company will post earnings per share of ($1.53) for the year, down from their previous estimate of ($1.45). Alector (NASDAQ:ALEC – Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. Weiss Ratings restated a “sell (d-)” rating on shares of Alector in a research note on Saturday, September 27th. Alector Company Profile(Get Free Report)Alector, Inc, a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases.